Ferrannini, E. *see* Solini, A.
Fioretto, P. *see* Solini, A.
Fontana, D. *see* Coppola, A.
Forli, L., Halse, J., Haug, E., Bjørtuft, Ø., Vatn, M., Kofstad, J. & Boe, J. Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease, 56
Fratiglioni, L. *see* Winblad, B.
Fujii, H. *see* Sato, T.
Fukuchi, Y. *see* Sato, T.

Gansevoort, R.T. *see* Verhave, J.C.
Gansevoort, R.T. *see* Wulffelé, M.G.
Gareeboo, H. *see* Söderberg, S.
Georgiades, A. *see* Janszky, I.
Giacobini, E. *see* Winblad, B.
Giannini, E.G. & Testa, R. Reply to Farina ti *et al.*: classification of 'intermediate stage', untreated hepatocellular carcinoma patients: the neighbour's grass is not so green, 531
Giugliano, D. *see* Coppola, A.
Glatthor, C. *see* Hausleiter, J.
Gøtzsche, P.C. *see* Hróbjartsson, A.
Graff, C. *see* Winblad, B.
Graff-Iversen, S., Hammar, N., Thelle, D.S. & Tonstad, S. Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women, 437
Grubb, A.O. *see* Christensson, A.G.

Hallmans, G. *see* Hultdin, J.
Halse, J. *see* Forli, L.
Hammar, N. *see* Graff-Iversen, S.
Hamsten, A. *see* Bartnik, M.
Hansson, T. *see* Midhagen, G.
Hardy, J. *see* Winblad, B.
Hargrove, F. *see* Hulgan, T.
Haug, E. *see* Forli, L.
Hausleiter, J., Kastrati, A., Mehilli, J., Schühlen, H., Pache, J., Dotzer, F., Glatthor, C., Siebert, S., Dirschinger, J., Schömig, A. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries, 388
Hedblad, B. *see* Janzon, E.
Heikens, J.T. *see* Stades, A.M.E.
Heine, R.J. *see* Spijkerman, A.M.W.
Held, P. *see* Wilhelmsen, L.
Henry, R.M.A. *see* Spijkerman, A.M.W.
Hillege, H.L. *see* Verhave, J.C.
Hino, O. *see* Sato, T.
Hiukka, A. *see* Leinonen, E.S.
Hoekstra, J.B.L. *see* Stades, A.M.E.
Holleman, F. *see* Stades, A.M.E.
Hollman, G., Ek, A.-C. & Olsson, A.G. Only one of four patients with familial hypercholesterolaemia reach cholesterol treatment goals in primary prevention, 176
Holm, G. & Fagrell, B. Promotion of clinical science Key Symposium series in the honour of Axel Key, a pioneer in medicine, 179
Holmberg, E. *see* Luik, E.
Holmgren, G., Wikström, L., Lundgren, H.-E. & Suhr, O.B. Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins, 453
Hróbjartsson, A. & Gøtzsche, P.C. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment, 91
Hulgan, T., Rosenbloom, S.T., Hargrove, F., Talbert, D.A., Arbogast, P.G., Bansal, P., Miller, R.A. & Kernodle, D.S. Oral quinolones in hospitalized patients: an evaluation of a computerized decision support intervention, 349
Hultcrantz, R. *see* Ormarsdóttir, S.
Hultdin, J., Thøgersen, A.M., Jansson, J.-H., Nilsson, T.K., Weinehall, L. & Hallmans, G. Elevated plasma homocysteine: cause or consequence of myocardial infarction?, 491
Hulthe, J. *see* Wallenfeldt, K.
Hurme, M. *see* Maury, C.P.J.
Hurt-Camejo, E. *see* Leinonen, E.S.

Imbert, B. *see* Labarere, J.
Irjala, K. *see* Wasén, E.
Isoaho, R. *see* Wasén, E.

Jack, C. *see* Winblad, B.
Jackson, S.L., Peterson, G.M., Vial, J.H. & Jupe, D.M.L. Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation, 137
Jansen, A.C.M., Aalst-Cohen, E.S., Tanck, M.W., Trip, M.D., Lansberg, P.J., Liem, A.H., Roeters van Lennep, H.W.O., Sijbrands, E.J.G. & Kastelein, J.J.P. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients, 482
Janssen, W.M.T. *see* Verhave, J.C.
Jansson, J.-H. *see* Hultdin, J.
Janszky, I., Ericson, M., Lekander, M., Blom, M., Buhlin, K., Georgiades, A. & Ahnve, S. Inflammatory markers and heart rate variability in women with coronary heart disease, 421
Janzon, E., Hedblad, B., Berglund, G. & Engström, G. Tobacco and myocardial infarction in middle-aged women: a study of factors modifying the risk, 111
Järnerot, G. *see* Midhagen, G.
Jelic, V. *see* Winblad, B.
Johansson, L. *see* Söderberg, S.
Johansson, P., Kutti, J., Andréasson, B., Safai-Kutti, S., Vilén, L., Wedel, H. & Ridell, B. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99, 161
Jones, S. *see* Bäckman, L.
de Jong, P.E. *see* Verhave, J.C.
Jorm, A. *see* Winblad, B.
Juntikka, E.-L. *see* Luik, E.
Jupe, D.M.L. *see* Jackson, S.L.

Kaarela, K. *see* Maury, C.P.J.
Kastelein, J.J.P. *see* Jansen, A.C.M.
Kastrati, A. *see* Hausleiter, J.
Kerkman, D. *see* de Leon, M.J.
Kernodle, D.S. *see* Hulgan, T.
Kesäniemi, Y.A. *see* Santaniemi, M.
Keynan, Y. & Pottesman, I. Neurological symptoms in a traveller returning from Central America, 174
Kinra, S. & Davey Smith, G. Differential transmission of coronary disease risk to offspring is not supported by evidence, 260
Kivelä, S.-L. *see* Wasén, E.
Kivipelto, M. *see* Winblad, B.
Kofstad, J. *see* Forli, L.
Kooy, A. *see* Wulffelé, M.G.
Kors, J.A. *see* Spijkerman, A.M.W.
Kostense, P.J. *see* Spijkerman, A.M.W.
Krakau, I. *see* Eriksson, M.
Kumasaka, T. *see* Sato, T.
Kupari, M., Turto, H. & Lommi, J. Diagnosing heart failure in aortic valve stenosis, 381
Kutti, J. *see* Johansson, P.
Kutti, J. *see* Luik, E.

Labarere, J., Bosson, J.-L., Brion, J.-P., Fabre, M., Imbert, B., Carpentier, P. & Pernod, G. Validation of a clinical guideline on prevention of venous thromboembolism in medical inpatients: a before-and-after study with systematic ultrasound examination. 338
Laiho, K. *see* Maury, C.P.J.
Laine, M., Luukkainen, R. & Toivanen, A. Sindbis viruses and other alphaviruses as cause of human arthritic disease. 457
Lair, L. *see* de Leon, M.J.
Lansberg, P.J. *see* Jansen, A.C.M.
Lappas, G. *see* Wilhelmsen, L.
Laukka, E.J. *see* Bäckman, L.
Lavi, D. *see* Ofran, Y.
Leinonen, E.S., Hiukka, A., Hurt-Camejo, E., Wiklund, O., Sarna, S.S., Mattson Hultén, L., Westerbacka, J., Salonen, R.M., Salonen, J.T. & Taskinen, M.-R. Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. 119
Lekander, M. *see* Janszky, I.
de Leon, M.J., DeSanti, S., Zinkowski, R., Mehta, P.D., Pratico, D., Segal, S., Clark, C., Kerkman, D., DeBernardis, J., Li, J., Lair, L., Reisberg, B., Tsui, W. & Rusinek, H. MRI and CSF studies in the early diagnosis of Alzheimer's disease. 205
Leosdottir, M., Nilsson, P., Nilsson, J.-Å., Månsson, H. & Berglund, G. The association between total energy intake and early mortality: data from the Malmö Diet and Cancer Study. 499
Li, J. *see* de Leon, M.J.
Liem, A.H. *see* Jansen, A.C.M.
Liguori, E. *see* Coppola, A.
Liljeström, M. *see* Maury, C.P.J.
Lind, S., Olsson, A.G., Eriksson, M., Rudling, M., Eggertsen, G. & Angelin, B. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. 406
Lip, G.Y.H. *see* Nadar, S.K.
Lommi, J. *see* Kupari, M.
Lööf, L. *see* Ormarsdóttir, S.
Lowe, G.D.O. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. 361
Luik, E., Palk, K., Everaus, H., Varik, M., Aareleid, T., Wennström, L., Juntikka, E.-L., Safai-Kutti, S., Stockelberg, D., Holmberg, E. & Kutti, J. The incidence and survival of acute *de novo* leukaemias in Estonia and in a well-defined region of western Sweden during 1982–1996: a survey of patients aged > 65 years. 79
Lundgren, H.-E. *see* Holmgren, G.
Luukkainen, R. *see* Laine, M.

Majamaa-Voltti, K. *see* Vikman, S.
Mallmin, H. *see* Ormarsdóttir, S.
Malmberg, K. *see* Bartnik, M.
Månsson, H. *see* Leosdottir, M.
Mantovani, A. *see* Simon, A.
Marino, D. *see* Farinati, F.
Marklund, N., Peltonen, M., Nilsson, T.K. & Olsson, T. Low and high circulating cortisol levels predict mortality and cognitive dysfunction early after stroke. 15
Mattila, K. *see* Wasén, E.
Mattson Hultén, L. *see* Leinonen, E.S.
Maury, C.P.J., Liljeström, M., Laiho, K., Tiitinen, S., Kaarela, K. & Hurme, M. Anaemia of chronic disease in AA amyloidosis is associated with allele 2 of the interleukin-1$\beta$-511 promoter gene and raised levels of interleukin-1$\beta$ and interleukin-18. 145
van der Meer, J.W.M. *see* Bleijenberg, G.
van der Meer, J.W.M. *see* Simon, A.
Mehilli, J. *see* Hausleiter, J.
Mehta, P.D. *see* de Leon, M.J.
Mezzatesta, G. *see* Mulè, G.
Midhagen, G., Åberg, A.-K., Olcén, P., Järnerot, G., Valdimarsson, T., Dahlbom, I., Hansson, T. & Ström, M. Antibody levels in adult patients with coeliac disease during gluten-free diet: a rapid initial decrease of clinical importance. 519
Miller, R.A. *see* Hulgan, T.
Mongiovì, R. *see* Mulè, G.
Mulè, G., Cottone, S., Vadalà, A., Volpe, V., Mezzatesta, G., Mongiovì, R., Piazza, G., Nardi, E., Andronico, G. & Cerasola, G. Relationship between albumin excretion rate and aortic stiffness in untreated essential hypertensive patients. 22

Nadar, S.K., Blann, A.D. & Lip, G.Y.H. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy. 331
Naessén, T. *see* Ormarsdóttir, S.
Nannipieri, M. *see* Solini, A.
Nardi, E. *see* Mulè, G.
Nasic, S. *see* Eliasson, M.
Navis, G.J. *see* Verhave, J.C.
Niemelä, K. *see* Vikman, S.
Niemelä, M. *see* Vikman, S.
Nieminen, M.S. *see* Vikman, S.
Nijpels, G. *see* Spijkerman, A.M.W.
Nilsson, J.-Å. *see* Christensson, A.G.
Nilsson, J.-Å. *see* Leosdottir, M.
Nilsson, J.-Å. *see* Nilsson, P.M.
Nilsson, P. *see* Fagerberg, B.
Nilsson, P. *see* Leosdottir, M.
Nilsson, P.M., Nilsson, J.-Å. & Berglund, G. Reply to: Family history of CVD: the mother–son link revisited. 261
Nilsson, T.K. *see* Hultdin, J.
Nilsson, T.K. *see* Marklund, N.
Nordberg, A. *see* Winblad, B.
Norhammar, A. *see* Bartnik, M.
Norrgren, K. *see* Christensson, A.G.

Ofran, Y., Lavi, D., Opher, D., Weiss, T.A. & Elinav, E. Fatal voluntary salt intake resulting in the highest ever documented sodium plasma level in adults (255 mmol $L^{-1}$): a disorder linked to female gender and psychiatric disorders. 525
Öhrvik, J. *see* Bartnik, M.
Olcén, P. *see* Midhagen, G.
Oliviero, M. *see* Coppola, A.
Olsson, A.G. *see* Hollman, G.
Olsson, A.G. *see* Lind, S.
Olsson, T. *see* Marklund, N.
Olsson, T. *see* Söderberg, S.
Opher, D. *see* Ofran, Y.
Ormarsdóttir, S., Mallmin, H., Naessén, T., Petrén-Mallmin, M., Broomé, U., Hultcrantz, R. & Lööf, L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. 63

Pache, J. *see* Hausleiter, J.
Palk, K. *see* Luik, E.
Palmer, K. *see* Winblad, B.
Passaro, A. *see* Solini, A.
Peltonen, M. *see* Marklund, N.
Perneger, T. *see* Bernard Bagattini, S.
Pernod, G. *see* Labarere, J.
Perrier, A. *see* Bernard Bagattini, S.
Petersen, R.C. *see* Winblad, B.
Petersen, R.C. Mild cognitive impairment as a diagnostic entity. 183

Peterson, G.M. *see* Jackson, S.L.
Petrén-Mallmin, M. *see* Ormarsdóttir, S.
Petrozzi, L. *see* Vassalle, C.
Peuhkurinen, K. *see* Vikman, S.
Piazza, G. *see* Mulè, G.
Pottesman, I. *see* Keynan, Y.
Pratico, D. *see* de Leon, M.J.

Reisberg, B. *see* de Leon, M.J.
Ridell, B. *see* Johansson, P.
Ritchie, K. *see* Winblad, B.
Ritt, M. Reply to: metformin – current restrictions should be alleviated, 359
Rodu, B. *see* Eliasson, M.
Roeters van Lennep, H.W.O. *see* Jansen, A.C.M.
Rolandsson, O. What is the mechanism behind the association between autoantibodies against GAD65 and high body mass index?, 262
Rosenbloom, S.T. *see* Hulgan, T.
Rosengren, A. *see* Wilhelmsen, L.
Rudling, M. *see* Lind, S.
Rusinek, H. *see* de Leon, M.J.
Ruwaard, D. *see* Spijkerman, A.M.W.
Rydén, L. *see* Bartnik, M.

Safai-Kutti, S. *see* Johansson, P.
Safai-Kutti, S. *see* Luik, E.
Salonen, J.T. *see* Leinonen, E.S.
Salonen, R.M. *see* Leinonen, E.S.
Santaniemi, M., Ukkola, O. & Kesäniemi, Y.A. Tyrosine phosphatase 1B and leptin receptor genes and their interaction in type 2 diabetes, 48
Sarna, S.S. *see* Leinonen, E.S.
Sato, T., Seyama, K., Kumasaka, T., Fujii, H., Setoguchi, Y., Shirai, T., Tomino, Y., Hino, O. & Fukuchi, Y. A patient with *TSC1* germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis, 166
Schölin, A. & Sundkvist, G. Reply to: what is the mechanism behind the association between autoantibodies against GAD6S and high body mass index?, 264
Schömig, A. *see* Hausleiter, J.
Schühlen, H. *see* Hausleiter, J.
Segal, S. *see* de Leon, M.J.
Setoguchi, Y. *see* Sato, T.
Seyama, K. *see* Sato, T.
Shaw, J. *see* Söderberg, S.
Shirai, T. *see* Sato, T.
Siebert, S. *see* Hausleiter, J.
Sijbrands, E.J.G. *see* Jansen, A.C.M.
Silveira, A. *see* Bartnik, M.
Simon, A., Bijzet, J., Voorbij, H.A.M., Mantovani, A., van der Meer, J.W.M. & Drenth, J.P.H. Effect of inflammatory attacks in the classical type hyper-IgD syndrome on immunoglobin D, cholesterol and parameters of the acute phase response, 247
Siris, E.S. *see* Wehren, L.E.
Sjöström, L.-G. *see* Söderberg, S.
Small, B.J. *see* Bäckman, L.
Söderberg, S., Stegmayr, B., Stenlund, H., Sjöström, L.-G., Ågren, Å., Johansson, L., Weinehall, L. & Olsson, T. Leptin, but not adiponectin, predicts stroke in males, 128
Söderberg, S., Zimmet, P., Tuomilehto, J., de Courten, M., Dowse, G.K., Chitson, P., Stenlund, H., Gareeboo, H., Alberti, K.G.M.M. & Shaw, J. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius, 37
Solini, A., Passaro, A., Fioretto, P., Nannipieri, M. & Ferrannini, E. Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes, 30
Spijkerman, A.M.W., Henry, R.M.A., Dekker, J.M., Nijpels, G., Kostense, P.J., Kors, J.A., Ruwaard, D., Stehouwer, C.D.A., Bouter, L.M. & Heine, R.J. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study, 429
Stades, A.M.E., Heikens, J.T., Holleman, F. & Hoekstra, J.B.L. Metformin – current restrictions should be alleviated, 358
Stegmayr, B. *see* Söderberg, S.
Stehouwer, C.D.A. *see* Spijkerman, A.M.W.
Stehouwer, C.D.A. *see* Wulffelé, M.G.
Stenlund, H. *see* Söderberg, S.
Sterner, G. *see* Christensson, A.G.
Stockelberg, D. *see* Luik, E.
Stouten, B. Chronic fatigue syndrome: a clinical and laboratory study with a well-matched control group, 265
Ströhle, A. & Wolters, M. Comment on the article 'Genotype, obesity and cardiovascular disease – has technical and social advancement outstripped evolution?', 86
Ström, M. *see* Midhagen, G.
Suhr, O.B. *see* Holmgren, G.
Sundkvist, G. *see* Christensson, A.G.
Sundkvist, G. *see* Schölin, A.
Svärdsudd, K. *see* Björkegren, K.
Svärdsudd, K. *see* Eriksson, M.

Talbert, D.A. *see* Hulgan, T.
Tanck, M.W. *see* Jansen, A.C.M.
Taskinen, M.-R. *see* Leinonen, E.S.
Tenerz, Å. *see* Bartnik, M.
Testa, R. *see* Giannini, E.G.
Thelle, D.S. *see* Graff-Iversen, S.
Thøgersen, A.M. *see* Hultdin, J.
Tierala, I. *see* Vikman, S.
Tiitinen, S. *see* Maury, C.P.J.
Toivanen, A. *see* Laine, M.
Tomino, Y. *see* Sato, T.
Tonstad, S. *see* Graff-Iversen, S.
Trevisani, F. *see* Farinati, F.
Trip, M.D. *see* Jansen, A.C.M.
Tsui, W. see de Leon, M.J.
Tumber, M.B. & Dickersin, K. Publication of clinical trials: accountability and accessibility, 271
Tuomilehto, J. *see* Söderberg, S.
Turto, H. *see* Kupari, M.
Tuunanen, H. *see* Vikman, S.

Ukkola, O. *see* Santaniemi, M.

Vadalà, A. *see* Mulè, G.
Vahlberg, T. *see* Wasén, E.
Valdimarsson, T. *see* Midhagen, G.
Varik, M. *see* Luik, E.
Vassalle, C., Petrozzi, L., Botto, N., Andreassi, M.G. & Zucchelli, G.C. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors, 308
Vatn, M. *see* Forli, L.
Vercoulen, J.H.H.M. *see* Bleijenberg, G.
Verhave, J.C., Hillege, H.L., Burgerhof, J.G.M., Janssen, W.M.T., Gansevoort, R.T., Navis, G.J., de Zeeuw, D., de Jong, P.E. for the PREVEND study group, Sodium intake affects urinary albumin excretion especially in overweight subjects, 324
Vial, J.H. *see* Jackson, S.L.

Vikman, S., Airaksinen, K.E.J., Tierala, I., Peuhkurinen, K., Majamaa-Voltti, K., Niemelä, M., Tuunanen, H., Nieminen, M.S. & Niemelä, K. Improved adherence to practice guidelines yields better outcome in high-risk patients with acute coronary syndrome without ST elevation: findings from nationwide FINACS studies, 316
Vilén, L. *see* Johansson, P.
Visser, P. *see* Winblad, B.
Volpe, V. *see* Mulè, G.
Voorbij, H.A.M. *see* Simon, A.

Wahlund, L.-O. *see* Winblad, B.
Wallander, M.-A. *see* Eriksson, M.
Wallenfeldt, K., Fagerberg, B., Wikstrand, J. & Hulthe, J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men, 413
Wasén, E., Isoaho, R., Mattila, K., Vahlberg, T., Kivelä, S.-L. & Irjala, K. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin C, 70
Wedel, H. *see* Eriksson, M.
Wedel, H. *see* Johansson, P.
Wedel, H. *see* Wilhelmsen, L.
Wehren, L.E. & Siris, E.S. Beyond bone mineral density: can existing clinical risk assessment instruments identify women at increased risk of osteoporosis?, 375
Weinehall, L. *see* Hultdin, J.
Weinehall, L. *see* Söderberg, S.
Weiss, T.A. *see* Ofran, Y.
Wennström, L. *see* Luik, E.
Westerbacka, J. *see* Leinonen, E.S.
Wiklund, O. *see* Leinonen, E.S.
Wikstrand, J. *see* Wallenfeldt, K.
Wikström, L. *see* Holmgren, G.
Wilhelmsen, L., Held, P. & Wedel, H. Clinical trials: a summary, 284
Wilhelmsen, L., Lappas, G. & Rosengren, A. Risk of coronary events by baseline factors during 28 years follow-up and three periods in a random population sample of men, 298
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V. & Fratiglioni, L. Introduction: Mild cognitive impairment: beyond controversies, towards a consensus, 181
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L.-O., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., Arai, H., Basun, H., Blennow, K., De Leon, M., DeCarli, C., Erkinjuntti, T., Giacobini, E., Graff, C., Hardy, J., Jack, C., Jorm, A., Ritchie, K., van Duijn, C., Visser, P. & Petersen, R.C. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, 240
Wolters, M. *see* Ströhle, A.
Wulffelé, M.G., Kooy, A., de Zeeuw, D., Stehouwer, C.D.A. & Gansevoort, R.T. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review, 1

de Zeeuw, D. *see* Verhave, J.C.
de Zeeuw, D. *see* Wulffelé, M.G.
Zimmet, P. *see* Söderberg, S.
Zinkowski, R. *see* de Leon, M.J.
Zucchelli, G.C. *see* Vassalle, C.

# Keyword index


acute
  coronary syndrome. 316
  *de novo* leukaemia. 79
  myocardial infarction. 288
  phase response. 247
adiponectin. 128
adult height. 472
ageing. 183
albumin. 491
alphaviruses. 457
Alzheimer's disease. 183. 195. 205. 224. 240
amyloidosis. 145. 453
anaemia of chronic disease. 145
angiopoietin-1. 331
antibiotics. 349
antibody response. 519
anticoagulation. 137
antioxidant. 398
aortic
  stiffness. 22
  valve stenosis. 381
arterial hypertension. 22
atheroma. 413
atherosclerosis. 308. 413
authorship. 271
autosomal recessive hypercholesterolaemia. 406

balloon angioplasty. 388
β-amyloid. 224
biliary. 63
biomarkers. 205. 224
birth weight. 254. 472
blood pressure. 1. 254
body
  composition. 56
  size. 254
bone
  density. 63
  mineral density. 56
  mineral density testing. 375

calcium channel blockers. 331
caloric intake. 499
cancer. 499
cardiovascular. 499
  disease. 429. 437. 472. 482
  risk. 22
  risk factor. 324
cerebrospinal fluid. 224
chemokines. 398
cholesterol. 1. 111
Ciguatera. 174
Ciguatoxin. 174
clinical
  criteria. 240
  decision support systems. 349
  trials. 271
coagulation. 361
Cockcroft-Gault formula. 70
coeliac disease. 519
cognition. 15. 195
cohort studies. 37. 101
conflict of interest. 271
consensus. 240
contiguous gene syndrome. 166
coronary
  artery disease. 308. 388
  circulation. 398
  heart disease. 298. 361. 421. 437. 472
cortisol. 15
C-reactive protein. 421
creatinine. 491. 510
CVD. 119
cystatin C. 510

definition. 240
dehydroepiandrosterone sulphate. 15
diabetes. 119. 288. 472. 510
  mellitus. 37. 101
nephropathy. 30
diagnosis. 153. 224
diet. 519
differential diagnosis. 153
disorientation. 15
Doppler echo-cardiography. 381
dysesthesia. 174
dyslipidaemia. 288

early diagnosis. 205. 429
education. 137. 316
electronic publishing. 271
endothelium. 119
epidemiology. 101. 429. 437
essential thrombocythaemia. 161
Estonia. 79
ezetimibe. 406

familial hypercholesterolaemia. 406
family history. 298
ferritin. 247
filtration. 30
fish poisoning. 174
folate. 446
forme fruste. 166

gene–gene interaction. 48
genetics. 453
genetics and dementia. 235
germline mutation. 166
glomerular. 30
  filtration rate. 70
glycoprotein IIb/IIIa antagonists. 388
guidelines. 316

haemorrhage. 137
haemorrhagic stroke. 128
heart
  failure. 381
  rate variability. 421
heparin. 338
high density lipoprotein. 254
homocysteine. 398. 446. 491
hormone
  replacement therapy. 63. 361
  treatment. 437
hypercholesterolaemia. 30. 482
hyper-IgD syndrome. 247
hypernatraemia. 525
hypertension. 111. 331

idiopathic myelofibrosis. 161
immunoglobulin D. 247
impaired fasting glucose. 37
impaired glucose tolerance. 37. 288
implementation. 316
incidence. 37. 79. 101. 161
inflammation. 119
INR monitoring. 137
interleukin-6. 421
interleukin-18. 145
interleukin-1
  polymorphisms. 145
  receptor antagonist. 421
  β-511 gene polymorphism. 145
ischaemic stroke. 15. 128
isoprostane. 308

Karelian fever. 457

LDL
  apheresis. 406
  cholesterol. 406. 413
leptin. 128
  receptor. 48
lipoprotein lipase polymorphisms. 30
liver cirrhosis. 63
longitudinal. 205
long-term follow-up. 298
lymphangioleiomyomatosis. 166

macrovascular complications. 429
markers. 195
Mauritius. 37
MCI. 205. 240
memory. 195
meta-analysis. 1. 91
metabolic syndrome. 119. 254
metformin. 1
methylmalonic acid. 446
microalbuminuria. 22. 30. 324
mild cognitive impairment. 183. 235. 240
Modification of Diet in Renal Disease formula. 70
mortality. 15. 499
MRI. 205
multivariate analysis. 153
myeloproliferative disorders. 161
myocardial infarction. 111. 491

natriuretic peptides. 381
nephropathy. 510
nested case-referent study. 128
neuropathy. 453

obesity. 324
occupation and marital status. 111
Ockelbo disease. 457
oestrogen. 63
oral. 525
osteoporosis. 63. 375
oxidative stress. 308

pain. 91
paresthesia. 174


© 2004 Blackwell Publishing Ltd

pentraxin-3. 247
placebo effect. 91
placebos. 91
platelet. 331. 388
Pogosta disease. 457
polycystic kidney disease. 166
polycythaemia vera. 161
population. 499
preclinical. 195
  dementia. 240
prediction rule. 153
prevalence. 101. 288
prevention. 338
procalcitonin. 247
P-selectin. 331
psychiatric. 525
publication bias. 271
publishing. 271
pulmonary
  disease. 56
  embolism. 153. 338
pulse wave velocity. 22

quinolones. 349

renal function. 510
restenosis. 388
risk
  assessment. 375
  determinants. 491
  factors. 128. 298. 375. 482
  stratification. 316

screening. 375. 429
serum
  creatinine. 70
  cystatin C. 70
Sindbis viruses. 457
single nucleotide polymorphism. 48
smokeless. 101
smoking. 111
sodium. 525
statin. 406
stents. 388
stress. 298
stroke. 361
survival. 79
Sweden. 79
symptoms. 446
systematic review. 1. 91

tau proteins. 224
tobacco. 101
total antioxidant capacity. 308
transition. 195
transplantation. 56
treatment trial. 446
triglycerides. 1. 254
tuberous sclerosis complex. 166
type 2
  diabetes. 30. 48. 429
  diabetes mellitus. 1
tyrosine phosphatase 1B. 48

ultrasonography. 413
urinary sodium excretion. 324

vascular endothelial growth factor. 331
venous thrombosis. 338. 361
viral arthritis. 457
vitamin
  B12. 446
  D. 56

warfarin. 137
weight. 56
women. 111. 421
women's health. 437